Key Takeaways Johnson & Johnson shares advanced Tuesday after the pharmaceutical and medical device company posted better ...

Johnson & Johnson's stock was up in premarket trades Tuesday after the drugmaker reported better-than-expected third-quarter ...

Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected ...

The company also revised its operational earnings forecast from $10.05 to $9.91. The V-Wave acquisition is expected to dilute ...

Johnson & Johnson (JNJ) stock fell as the company lowered full-year earnings outlook while reporting better-than-expected Q3 ...

We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning with the consensus ...

Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4 ...

FDA批准这项联合疗法，主要是基于MARIPOSA临床3期研究的积极结果，分析显示，埃万妥单抗与甲磺酸兰泽替尼片与活性对照药物相比，可将疾病进展或死亡风险降低30%，联合疗法与活性对照药物组患者的中位无进展生存期 (PFS)分别为23.7个月与16.6个月;联合疗法组的中位DOR比活性对照药物长9个月 (25.8个月vs 16.7个月)。

People who voted to settle their baby power-related health claims against Johnson & Johnson should have their ballots thrown ...

强生 (JNJ.US)已完成对私人医疗设备公司V-Wave Ltd的收购。今年8月，这家制药巨头同意以6亿美元预付款收购V-Wave。该交易将被视为一项资产收购，在2024年第四季度将产生约6亿美元的在研研发费用 (IPR&D)。

The stock has also underperformed the sector as well as the S&P 500, as seen in the chart below. From a valuation standpoint, JNJ appears attractive relative to the industry and is trading below ...

智通财经APP获悉，强生(JNJ.US)表示，由于令人失望的数据，该公司已经停止其用于治疗肌肉浸润性膀胱癌(MIBC)患者的疗法TAR-200的二期研究。据悉，这项名为SunRISe-2的研究在对数据进行中期分析后停止，因为分析显示这种治疗方法并不比放化疗有优势。 不过，强生在一份声明中表示，该公司仍计划在2025年初向美国食品药品管理局(FDA)申请批准TAR-200作为非肌肉浸润性膀胱癌(NM ...